Enterococcus Faecium Infections Pipeline Review 2015 - 25 Companies & 40 Drug Profiles
M2 - Fri Jul 10, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pz9lr/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen, Inc. - Aphios Corporation - Cellceutix Corporation - ConjuGon, Inc. - ContraFect Corporation - Enanta Pharmaceuticals, Inc. - Helix BioMedix, Inc. - LegoChem Biosciences, Inc - Lytix Biopharma AS - Melinta Therapeutics, Inc - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nabriva Therapeutics AG - NovaBay Pharmaceuticals, Inc. - Novan, Inc. - NovoBiotic Pharmaceuticals, LLC - Omnia Molecular Ltd. - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited Drug Profiles - auriclosene - brilacidin tetrahydrochloride - CF-304 - chrysophaentin - closthioamide - EDP-788 - Epimerox - GP-505 - HB-1345 - HT-01 - HT-02 - IBN-1 - LCB-010371 - LCB-010699 - lefamulin - LTX-109 - Marinus - MBX-1162 - MGBBP-3 - MRX-I - MU-1140 - NAI-107 - NAI-603 - NVN-1000 - NVN-4428 - RX-05 - RXP-873 - SLP-0904 - SLP-0905 - SM-295291 - SM-369926 For more information visit http://www.researchandmarkets.com/research/6p...terococcus
ENTA: 45.53 (+1.12), OGEN: 1.62 (+0.04)
Klebsiella Pneumoniae Infections Pipeline Review 2015 - 18 Companies & 34 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbn3w/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Cellceutix Corporation - Debiopharm International S.A. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Ltd. - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. Drug Profiles - Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - BXN-112 - CB-027 - CB-618 - CC-1807 - CTIX-1278 - Debio-1454 - dusquetide - IBN-1 - Klebsiella pneumoniae vaccine - Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Monoclonal Antibody for Klebsiella Pneumoniae Infections - MVX-506 - NAB-7061 - NAB-739 - NAB-741 - NOSO-95300 - NVN-1000 - NVN-4428 - PT-4 - RX-05 - RXP-792 - RXP-873 - S-649266 - Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - SM-295291 - SM-369926 - Small Molecule for Gram-Negative Nosocomial Infections - Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - TP-076 - TP-138 - TP-600 For more information visit http://www.researchandmarkets.com/research/4kbn3w/klebsiella
TTPH: 48.76 (+2.09), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57)
Retinoblastoma - Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Wed Jun 24, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxghfl/retinoblastoma) has announced the addition of the "Retinoblastoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Cellceutix Corporation - Icon Bioscience, Inc. - Neotropix, Inc. - Recombio S.L - RXi Pharmaceuticals Corporation Drug Profiles - BL-8040 - Kevetrin - melphalan - NTX-010 - nutlin-3 - racotumomab - RNAi Oligonucleotide for Retinoblastoma For more information visit http://www.researchandmarkets.com/research/cx...noblastoma
Cellceutix's Fundamental Strength Outweighs Market Cap
Jim Bowie - at Seeking Alpha - Fri Jun 19, 10:36AM CDT
MRK: 57.95 (+0.57), AMGN: 154.10 (+2.79), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Cellceutix Provides Update on Uplist Application
Marketwired - Mon Jun 08, 6:58AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
Marketwired - Wed Jun 03, 8:27AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
Marketwired - Mon Jun 01, 7:11AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwired - Thu May 28, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
Marketwired - Tue May 26, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix to begin Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors in additional patients following IRB approval
M2 - Mon May 25, 5:49AM CDT
Biopharmaceutical company Cellceutix (OTC:CTIX) revealed on Friday that the Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has been approved for additional patient enrollment.
IRB Approves Additional Enrollment in Cellceutix's Clinical Trial of New Cancer Drug Candidate for Solid Tumors
Marketwired - Fri May 22, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
Marketwired - Wed May 13, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix Selects Independent Directors and Committee Members
Marketwired - Mon Apr 27, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
CellCeutix: Comparing Brilacidin With SoC Daptomycin
Kanak Kanti De - at Seeking Alpha - Tue Apr 21, 12:37PM CDT
Cellceutix Provides Corporate Update
Marketwired - Tue Apr 21, 9:06AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix PIND Meeting Scheduled With FDA for Hidradenitis Suppurativa
Marketwired - Mon Apr 13, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Cellceutix Corporation - Product Pipeline Review - 2015
M2 - Thu Apr 09, 1:48AM CDT
Summary
Cellceutix closes $30M stock purchase agreement
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 7:59AM CDT
Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement
Marketwired - Wed Apr 01, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
Marketwired - Tue Mar 24, 7:29AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"